MDM4 is a homologue of MDM2, serving cooperatively as the negative regulator of tumor
suppressor p53. Under the shadow of MDM2 inhibitors, limited efforts had been put into the …

MDM2 is a primary cellular inhibitor of p53. It inhibits p53 function by multiple mechanisms,
each of which, however, is mediated by their direct interaction. It has been proposed that …

Inactivation of the tumor suppressor p53 and/or overexpression of the oncogene MDM2
frequently occur in human cancers, and are associated with poor prognosis, advanced forms …

The p53 tumor suppressor is controlled by MDM2, which binds p53 and negatively regulates
its transcriptional activity and stability. Many tumors overproduce MDM2 to impair p53 …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

Inactivation of the function of tumor suppressor p53 is common in human cancers. In
approximately half of human cancers, the tumor suppressor function of p53 is inactivated by …

The MDM2 oncogene is overexpressed in various human cancers. Its expression correlates
with the phenotypes of high-grade, late-stage, and more resistant tumors. The auto …

The tumor suppressor p53 plays a central role in anti-tumorigenesis and cancer therapy. It
has been described as “the guardian of the genome”, because it is essential for conserving …

In this early phase of the new era of molecularly targeted patient friendly cancer
chemotherapy, there is a need for novel viable anticancer molecular targets. The MDM2 …

The discovery of the key negative regulator MDM2 (mouse double minute 2, also termed
HDM2 for its human equivalent) provided a great opportunity to manipulate the levels of the …